What is Iksuda Therapeutics?
Founded in 2007 and headquartered in Newcastle upon Tyne, UK, Iksuda Therapeutics is a biotechnology firm dedicated to pioneering next-generation Antibody Drug Conjugates (ADCs). The company's focus lies in developing advanced ADCs engineered to confront challenging and treatment-resistant tumors. Iksuda's innovative pipeline is built upon its proprietary PermaLink® conjugation platform, coupled with a suite of potent cytotoxic payloads designed to maximize antitumor efficacy and ultimately improve patient outcomes in oncology.
How much funding has Iksuda Therapeutics raised?
Iksuda Therapeutics has raised a total of $47M across 1 funding round:
Unspecified
$47M
Unspecified (2021): $47M with participation from Celltrion, Premier Partners, and Mirae Asset Capital Co,Ltd
Key Investors in Iksuda Therapeutics
Celltrion
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company specializing in biosimilar and innovative drug development. They aim to provide more accessible advanced therapeutics to patients globally.
Premier Partners
Premier Partners, operating through Vimexx, offers domain registration, transfer, and web hosting solutions, catering to individuals and businesses seeking an online presence. They also provide VPS and dedicated server options for enhanced performance.
Mirae Asset Capital Co,Ltd
Mirae Asset Capital Co Ltd is an investment banking firm based in Seoul, South Korea, focusing on capital markets and financial services.
What's next for Iksuda Therapeutics?
The substantial enterprise-level capital infusion positions Iksuda Therapeutics for accelerated growth and further development of its ADC pipeline. This strategic investment is expected to fuel advancements in its PermaLink® platform and the expansion of its therapeutic offerings, potentially enabling the company to tackle a broader range of difficult-to-treat cancers. The company's trajectory suggests a move towards scaling its operations and advancing its lead candidates through clinical trials, solidifying its role as a key player in the advanced cancer therapeutics market.
See full Iksuda Therapeutics company page
